Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Prueba de la combinación de un fármaco anticancerígeno, Iadademstat, con otros fármacos anticancerígenos (Atezolizumab o Durvalumab) para mejorar los resultados del cáncer de pulmón de células pequeñas

13 de noviembre de 2026 actualizado por: National Cancer Institute (NCI)

Un ensayo aleatorizado de fase I y de fase II de Iadademstat combinado con mantenimiento de inhibición de puntos de control inmunológico después de la quimioinmunoterapia inicial en pacientes con cáncer de pulmón de células pequeñas en estadio extenso

This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spread outside of the lung in which it began or to other parts of the body (extensive stage) who initially received standard of care chemotherapy and immunotherapy. Iadademstat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab or durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding iadademstat to either atezolizumab or durvalumab may be able to stabilize cancer for longer than atezolizumab or durvalumab alone in treating patients with extensive stage small cell lung cancer.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

PRIMARY OBJECTIVE:

I. To compare the progression-free survival (PFS) between the combination of iadademstat plus immune checkpoint inhibitor (ICI) versus ICI maintenance alone.

SECONDARY OBJECTIVES:

I. To compare objective response rate (ORR) and overall survival (OS) between treatment arms.

II. To evaluate the safety of combination iadademstat plus ICI.

EXPLORATORY OBJECTIVES:

I. To assess whether detection of circulating tumor deoxyribonucleic acid (DNA) (ctDNA) minimal residual disease correlates with disease progression.

II. To assess whether iadademstat impacts the correlation of ICI (atezolizumab or durvalumab) baseline and time varying clearance with clinical outcomes (PFS and OS) and the presence of cachexia.

III. To explore exposure response relationships of iadademstat in combination with ICIs.

IV. To characterize changes to small cell lung cancer (SCLC) subtype throughout treatment.

OUTLINE: This is a phase I dose-escalation study of iadademstat in combination with atezolizumab and durvalumab followed by a randomized phase II study.

PHASE I: Patients receive iadademstat orally (PO) on days 1, 8, 15, and 22 or days 1 and 15 of each cycle. Patients also continue receiving their initial ICI treatment, either atezolizumab intravenously (IV) over 30-60 minutes on day 1 of each cycle or durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

PHASE II: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive iadademstat PO on days 1, 8, 15, and 22 or days 1 and 15 of each cycle. Patients also continue receiving their initial ICI treatment, either atezolizumab IV over 30-60 minutes on day 1 of each cycle or durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

ARM II: Patients continue receiving their initial ICI treatment, either atezolizumab IV over 30-60 minutes on day 1 of each cycle or durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

All patients also undergo multi-gated acquisition (MUGA) or echocardiogram (ECHO), brain magnetic resonance imaging (MRI) or brain computed tomography (CT) during screening, and CT scans and blood and urine sample collection throughout the trial. Patients may also undergo an optional tumor biopsy on study.

After completion of study treatment, patients are followed up every 3 months for up to 12 months.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

45

Fase

  • Fase 2
  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • California
      • Duarte, California, Estados Unidos, 91010
        • Reclutamiento
        • City of Hope Comprehensive Cancer Center
        • Contacto:
        • Investigador principal:
          • Matthew Lee
      • Irvine, California, Estados Unidos, 92618
        • Reclutamiento
        • City of Hope at Irvine Lennar
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 877-467-3411
        • Investigador principal:
          • Matthew Lee
      • La Jolla, California, Estados Unidos, 92093
        • Reclutamiento
        • UC San Diego Moores Cancer Center
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 858-822-5354
          • Correo electrónico: cancercto@ucsd.edu
        • Investigador principal:
          • Lyudmila A. Bazhenova
      • Sacramento, California, Estados Unidos, 95817
        • Reclutamiento
        • University of California Davis Comprehensive Cancer Center
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 916-734-3089
        • Investigador principal:
          • Surbhi Singhal
    • Connecticut
      • Hartford, Connecticut, Estados Unidos, 06105
        • Suspendido
        • Smilow Cancer Hospital Care Center at Saint Francis
      • New Haven, Connecticut, Estados Unidos, 06520
        • Reclutamiento
        • Yale University
        • Investigador principal:
          • Anne C. Chiang
        • Contacto:
      • North Haven, Connecticut, Estados Unidos, 06473
        • Reclutamiento
        • Yale-New Haven Hospital North Haven Medical Center
        • Investigador principal:
          • Anne C. Chiang
        • Contacto:
      • Stamford, Connecticut, Estados Unidos, 06902
        • Suspendido
        • Smilow Cancer Hospital Care Center at Long Ridge
      • Trumbull, Connecticut, Estados Unidos, 06611
        • Reclutamiento
        • Smilow Cancer Hospital Care Center-Trumbull
        • Investigador principal:
          • Anne C. Chiang
        • Contacto:
    • District of Columbia
      • Washington D.C., District of Columbia, Estados Unidos, 20007
        • Reclutamiento
        • MedStar Georgetown University Hospital
        • Investigador principal:
          • Stephen V. Liu
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 202-444-2223
    • Florida
      • Gainesville, Florida, Estados Unidos, 32610
        • Reclutamiento
        • UF Health Cancer Institute - Gainesville
        • Investigador principal:
          • Aline F. Fares
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 352-273-8010
      • Tampa, Florida, Estados Unidos, 33612
        • Suspendido
        • Moffitt Cancer Center
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Reclutamiento
        • Emory University Hospital/Winship Cancer Institute
        • Investigador principal:
          • Ticiana A. Leal
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 404-778-1868
      • Atlanta, Georgia, Estados Unidos, 30308
        • Reclutamiento
        • Emory University Hospital Midtown
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 888-946-7447
        • Investigador principal:
          • Ticiana A. Leal
      • Atlanta, Georgia, Estados Unidos, 30342
        • Reclutamiento
        • Emory Saint Joseph's Hospital
        • Investigador principal:
          • Ticiana A. Leal
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 404-851-7115
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637
        • Reclutamiento
        • University of Chicago Comprehensive Cancer Center
        • Contacto:
        • Investigador principal:
          • Noura Choudhury
      • New Lenox, Illinois, Estados Unidos, 60451
        • Reclutamiento
        • UC Comprehensive Cancer Center at Silver Cross
        • Contacto:
        • Investigador principal:
          • Noura Choudhury
      • Orland Park, Illinois, Estados Unidos, 60462
        • Reclutamiento
        • University of Chicago Medicine-Orland Park
        • Contacto:
        • Investigador principal:
          • Noura Choudhury
    • Indiana
      • Crown Point, Indiana, Estados Unidos, 46307
        • Reclutamiento
        • UChicago Medicine Northwest Indiana
        • Contacto:
        • Investigador principal:
          • Noura Choudhury
    • Kansas
      • Fairway, Kansas, Estados Unidos, 66205
        • Reclutamiento
        • University of Kansas Clinical Research Center
        • Investigador principal:
          • Chao H. Huang
        • Contacto:
      • Kansas City, Kansas, Estados Unidos, 66160
        • Reclutamiento
        • University of Kansas Cancer Center
        • Investigador principal:
          • Chao H. Huang
        • Contacto:
      • Overland Park, Kansas, Estados Unidos, 66211
        • Reclutamiento
        • University of Kansas Hospital-Indian Creek Campus
        • Investigador principal:
          • Chao H. Huang
        • Contacto:
      • Westwood, Kansas, Estados Unidos, 66205
        • Reclutamiento
        • University of Kansas Hospital-Westwood Cancer Center
        • Investigador principal:
          • Chao H. Huang
        • Contacto:
    • Kentucky
      • Lexington, Kentucky, Estados Unidos, 40536
        • Reclutamiento
        • University of Kentucky/Markey Cancer Center
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 859-257-3379
        • Investigador principal:
          • Zhonglin Hao
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21287
        • Reclutamiento
        • Johns Hopkins University/Sidney Kimmel Cancer Center
        • Investigador principal:
          • Christine L. Hann
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 410-955-8804
          • Correo electrónico: jhcccro@jhmi.edu
      • Baltimore, Maryland, Estados Unidos, 21201
        • Reclutamiento
        • University of Maryland/Greenebaum Cancer Center
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 800-888-8823
        • Investigador principal:
          • Samuel Rosner
    • New Jersey
      • Basking Ridge, New Jersey, Estados Unidos, 07920
        • Suspendido
        • Memorial Sloan Kettering Basking Ridge
      • Middletown, New Jersey, Estados Unidos, 07748
        • Suspendido
        • Memorial Sloan Kettering Monmouth
      • Montvale, New Jersey, Estados Unidos, 07645
        • Suspendido
        • Memorial Sloan Kettering Bergen
    • New York
      • Commack, New York, Estados Unidos, 11725
        • Suspendido
        • Memorial Sloan Kettering Commack
      • Harrison, New York, Estados Unidos, 10604
        • Suspendido
        • Memorial Sloan Kettering Westchester
      • New York, New York, Estados Unidos, 10065
        • Reclutamiento
        • Memorial Sloan Kettering Cancer Center
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 212-639-7592
        • Investigador principal:
          • Charles M. Rudin
      • Uniondale, New York, Estados Unidos, 11553
        • Suspendido
        • Memorial Sloan Kettering Nassau
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28203
        • Reclutamiento
        • Carolinas Medical Center/Levine Cancer Institute
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 800-804-9376
        • Investigador principal:
          • Christopher R. Pallas
      • Concord, North Carolina, Estados Unidos, 28025
        • Reclutamiento
        • Atrium Health Cabarrus/LCI-Concord
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 800-804-9376
        • Investigador principal:
          • Christopher R. Pallas
      • Winston-Salem, North Carolina, Estados Unidos, 27157
        • Reclutamiento
        • Wake Forest University Health Sciences
        • Investigador principal:
          • Jimmy Ruiz
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 336-713-6771
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45219
        • Reclutamiento
        • University of Cincinnati Cancer Center-UC Medical Center
        • Investigador principal:
          • Jennifer Leddon
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 513-584-7698
          • Correo electrónico: cancer@uchealth.com
      • Cleveland, Ohio, Estados Unidos, 44106
        • Reclutamiento
        • Case Western Reserve University
        • Investigador principal:
          • Afshin Dowlati
        • Contacto:
      • Columbus, Ohio, Estados Unidos, 43210
        • Reclutamiento
        • Ohio State University Comprehensive Cancer Center
        • Investigador principal:
          • Asrar AlAhmadi
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 800-293-5066
          • Correo electrónico: Jamesline@osumc.edu
      • West Chester, Ohio, Estados Unidos, 45069
        • Reclutamiento
        • University of Cincinnati Cancer Center-West Chester
        • Investigador principal:
          • Jennifer Leddon
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 513-584-7698
          • Correo electrónico: cancer@uchealth.com
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Estados Unidos, 15232
        • Reclutamiento
        • UPMC Hillman Cancer Center
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 412-647-8073
        • Investigador principal:
          • Liza C. Villaruz
    • Virginia
      • Charlottesville, Virginia, Estados Unidos, 22908
        • Reclutamiento
        • University of Virginia Cancer Center
        • Contacto:
        • Investigador principal:
          • Ryan D. Gentzler
      • Richmond, Virginia, Estados Unidos, 23298
        • Reclutamiento
        • VCU Massey Comprehensive Cancer Center
        • Investigador principal:
          • Jonathan D. Berkman
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 804-628-6430
          • Correo electrónico: CTOclinops@vcu.edu

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Patients must have histologically or cytologically confirmed small cell lung cancer (SCLC)

  • Patients who have been treated with platinum etoposide chemotherapy plus either atezolizumab or durvalumab immunotherapy for at least 4 cycles, and no more than 6 cycles, with either a radiographic response or stable disease. Patients are eligible if a maximum of 2 cycles of atezolizumab or durvalumab were omitted with initial treatment

  • Age ≥ 18 years. Because no dosing or adverse event data are currently available on the use of iadademstat in combination with atezolizumab and durvalumab in patients <18 years of age, children are excluded from this study

  • Body weight ≥ 50 kg

  • Patient is able to swallow oral medications

  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%). This assessment for eligibility will take place after patients have received 4 cycles of standard of care (SOC) chemotherapy-ICI

  • Leukocytes ≥ 2,000/mcL

  • Lymphocyte count ≥ 500/mcL

  • Absolute neutrophil count ≥ 1,500/mcL

  • Hemoglobin ≥ 9 g/dL

  • Platelets ≥ 100,000/mcL

  • Albumin ≥ 3 g/dL

  • Total bilirubin ≤ 1.5 institutional upper limit of normal (ULN)

  • Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/ alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 3 × institutional ULN unless liver metastases are present, in which case it must be ≤ 5 × ULN

  • Glomerular filtration rate (GFR) ≥ 45 mL/min

  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated

  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

  • Patients with treated brain metastases (no escalating steroid use) or asymptomatic, untreated brain metastases (≤ 5 mm without significant edema) are eligible. Brain metastases must not be new after completion of chemotherapy

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

  • Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Pregnant women are excluded from this study because atezolizumab and durvalumab are monoclonal antibody agents with the potential for teratogenic or abortifacient effects. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:

    • Women < 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
    • Women ≥ 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses > 1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy)
  • The effects of iadademstat, atezolizumab, and durvalumab on the developing human fetus are unknown. For this reason and because monoclonal antibody agents are known to be teratogenic, women of child-bearing potential and males with females of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to registration, for the duration of study participation, and for 150 days after the last dose of study medication. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

    • Females of childbearing potential must agree to:

      • Use effective contraception during the trial and 150 days after the end of treatment.
      • Practice true abstinence during the trial and 150 days after the end of treatment.
      • Have a negative urine pregnancy test at screening.
      • Not to donate or freeze egg(s) during the course of this study or within 150 days after receiving their last dose of study drug.
    • Male patients even if surgically sterilized (i.e., status post-vasectomy) must agree to:

      • Use effective contraception during the entire study treatment period and through 150 days after the last dose of study drug.
      • Not to donate or freeze sperm during the course of this study or within 150 days after receiving their last dose of study drug.
  • Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with atezolizumab and durvalumab, female participants who are breastfeeding must agree to discontinue breastfeeding. These potential risks may also apply to iadademstat

  • Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants

Exclusion Criteria:

  • Patients who receive maintenance ICI therapy prior to cycle 1, day 1

  • Patients medicated with anti-depressants reported to have KDM1A/LSD1 inhibitory activity: Tranylcypromine or phenelzine

  • Patients who have not recovered from grade ≥2 adverse events (AEs) due to prior anti-cancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria.

    • Patients with grade ≥ 2 neuropathy will be evaluated on a case-by-case basis after consultation with the study physician
  • Patients who are receiving any other investigational agents or any other agent administered for the treatment of the patient's cancer within four half-lives or 4 weeks prior to registration, whichever is shorter

  • Treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-α or interleukin [IL]-2) within 4 weeks or five half-lives of the drug (whichever is longer) prior to cycle 1, day 1

  • Treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to registration or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions:

    • Patients who have received acute, low dose, systemic immunosuppressant medications or one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible after Principal Investigator confirmation has been obtained.
    • Patients who have received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenocortical insufficiency are eligible
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to iadademstat, atezolizumab, or durvalumab. In particular, a history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric antibodies, fusion proteins, or Chinese hamster ovary cell products or to any component of the atezolizumab formulation

  • Atezolizumab Concomitant Medication Considerations: Patients are not allowed to receive immunostimulatory agents, immunosuppressive medications, or herbal and natural remedies

  • Durvalumab Concomitant Medication Considerations: Patients are not allowed to receive immunosuppressive medications, EGFR TKIs, or herbal and natural remedies

  • Iadademstat Concomitant Medication Considerations: Patients are not allowed to receive prophylactic hematopoietic colony stimulating factors, any complementary or alternative medicine [any of various systems of healing or treating disease (as non-prescription drugs, herbal medicine and homeopathy)]. Use of these types of treatments must be terminated 1 week prior to registration

  • History of allogenic organ transplantation

  • Patients with active tuberculosis (TB)

  • Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous

  • History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted

  • Unstable angina, symptomatic or otherwise uncontrolled arrhythmia (does not include stable, lone atrial fibrillation), Fridericia's correction (QTcF) > 480 ms based on screening electrocardiogram (ECG), myocardial infarction ≤ 3 months prior to registration, cerebrovascular accidents ≤ 3 months before registration. Patient has congestive heart failure New York Heart Association (NYHA) class 2, 3 or 4 or patients with a history of congestive heart failure NYHA class 2, 3 or 4 in the past, unless a screening echocardiogram performed within 1 month prior to registration demonstrates a left ventricular ejection fraction that is ≥ 45%

  • History or risk of autoimmune disease, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis, with the following exceptions:

    • Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible.

    • Patients with controlled Type 1 diabetes mellitus (HbA1c < 8%) on a stable insulin regimen may be eligible.

    • Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided all of the following conditions are met:

      • Rash must cover less than 10% of body surface area (BSA).
      • Disease is well controlled at baseline and only requiring low potency topical steroids.
      • No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids) within the previous 12 months.
    • Any chronic skin condition that does not require systemic therapy.

    • Patients without active disease in the last 5 years may be included but only after consultation with the study physician.

    • Patients with celiac disease controlled by diet alone

  • Patients should not receive vaccines 30 days prior to registration. Patient is informed to not receive vaccines during treatment and through 30 days after the last dose of study treatment with the exception of seasonal influenza vaccines and vaccines intended to prevent SARS-CoV-2, pneumococcal infection and coronavirus disease 2019 (COVID-19). If a patient had received a live attenuated vaccine within 30 days of the first dose of trial treatment, eligibility should be discussed with the investigator

  • Patient has had major surgery within 4 weeks prior to registration

  • Patient has radiation therapy within 4 weeks prior to registration, excluding palliative and central nervous system (CNS) radiation

  • Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of iadademstat. In addition, patients with enteric stomata are also excluded

  • Patients with history of clinically significant bleeding, specifically any history of intracranial hemorrhage / hemorrhagic cardiovascular accident (CVA), or patients with gastrointestinal bleeding within the 3 months prior to registration

  • Patients with known irreversible bleeding disorders or receiving antiplatelet therapy for other indications

  • Patients with uncontrolled disseminated intravascular coagulation

  • Patients who refuse or are unable to potentially receive blood products

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Phase I (iadademstat, atezolizumab, durvalumab)

Patients in Phase I receive iadademstat PO on days 1, 8, 15, and 22 or days 1 and 15 of each cycle. Patients also continue receiving their initial ICI treatment, either atezolizumab IV over 30-60 minutes on day 1 of each cycle or durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MUGA or ECHO, brain MRI or brain CT during screening, and CT scans and blood and urine sample collection throughout the trial. Patients may also undergo an optional tumor biopsy on study.

Undergo MRI

Otros nombres:
  • Resonancia magnética
  • Resonancia magnetica
  • Exploración de imágenes por resonancia magnética
  • Imágenes Médicas, Resonancia Magnética / Resonancia Magnética Nuclear
  • SRES
  • Imágenes de RM
  • Imágenes de RMN
  • RMN
  • Imágenes de resonancia magnética nuclear
  • Imágenes por resonancia magnética (IRM)
  • resonancia magnética nuclear
  • Imágenes por resonancia magnética (procedimiento)
  • Resonancias magnéticas
  • Resonancia magnética estructural

Undergo ECHO

Otros nombres:
  • Ecocardiografía
  • CE

Undergo MUGA

Otros nombres:
  • Exploración de la piscina de sangre
  • Angiografía con radionúclidos de equilibrio
  • Imagen de piscina de sangre cerrada
  • MUGA
  • Ventriculografía con radionúclidos
  • RNVG
  • Escaneo SIMA
  • Escaneo de adquisición sincronizado de múltiples puertas
  • Escaneo MUGA
  • Escaneo de adquisición de puertas múltiples
  • Exploración de ventriculograma con radionúclidos
  • Escaneo de grupo de corazón cerrado
  • Escaneo RNV

Undergo CT scan

Otros nombres:
  • Connecticut
  • GATO
  • Análisis de gato
  • Tomografía Axial Computarizada
  • Tomografía axial computarizada
  • Tomografía computarizada
  • tomografía
  • Tomografía axial computarizada (procedimiento)
  • Tomografía computarizada (TC)
  • Escaneo de gato de diagnóstico
  • Tipo de servicio de escaneo de gato de diagnóstico

Undergo blood and urine sample collection

Otros nombres:
  • Recolección de muestras biológicas
  • Muestra biológica recolectada
  • Coleccion de especimenes
  • Recolección de muestras

Given IV

Otros nombres:
  • Tecentriq
  • MPDL3280A
  • RO5541267
  • RG7446
  • MPDL328OA
  • MPDL-3280A
  • RG-7446
  • RG 7446
  • RO 5541267
  • RO-5541267

Given IV

Otros nombres:
  • Imfinzi
  • Inmunoglobulina G1, anti-(proteína humana B7-H1) (cadena pesada monoclonal humana MEDI4736), disulfuro con cadena kappa monoclonal humana MEDI4736, dímero
  • MEDI-4736
  • MEDI4736
  • MEDIO 4736

Undergo optional tumor biopsy

Otros nombres:
  • Caja
  • BIOPSIA_TIPO
  • Biopsia

Given PO

Otros nombres:
  • ORIA 1001
  • ORY-1001
  • RG 6016
  • RG6016
  • RO 7051790
  • RO7051790
  • trans-N1-((1R,2S)-2-fenilciclopropil)-1,4-ciclohexanodiamina
Comparador activo: Phase II Arm II (atezolizumab, durvalumab)

Patients in Phase II Arm II continue receiving their initial ICI treatment, either atezolizumab IV over 30-60 minutes on day 1 of each cycle or durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MUGA or ECHO, brain MRI or brain CT during screening, and CT scans and blood and urine sample collection throughout the trial. Patients may also undergo an optional tumor biopsy on study.

Undergo MRI

Otros nombres:
  • Resonancia magnética
  • Resonancia magnetica
  • Exploración de imágenes por resonancia magnética
  • Imágenes Médicas, Resonancia Magnética / Resonancia Magnética Nuclear
  • SRES
  • Imágenes de RM
  • Imágenes de RMN
  • RMN
  • Imágenes de resonancia magnética nuclear
  • Imágenes por resonancia magnética (IRM)
  • resonancia magnética nuclear
  • Imágenes por resonancia magnética (procedimiento)
  • Resonancias magnéticas
  • Resonancia magnética estructural

Undergo ECHO

Otros nombres:
  • Ecocardiografía
  • CE

Undergo MUGA

Otros nombres:
  • Exploración de la piscina de sangre
  • Angiografía con radionúclidos de equilibrio
  • Imagen de piscina de sangre cerrada
  • MUGA
  • Ventriculografía con radionúclidos
  • RNVG
  • Escaneo SIMA
  • Escaneo de adquisición sincronizado de múltiples puertas
  • Escaneo MUGA
  • Escaneo de adquisición de puertas múltiples
  • Exploración de ventriculograma con radionúclidos
  • Escaneo de grupo de corazón cerrado
  • Escaneo RNV

Undergo CT scan

Otros nombres:
  • Connecticut
  • GATO
  • Análisis de gato
  • Tomografía Axial Computarizada
  • Tomografía axial computarizada
  • Tomografía computarizada
  • tomografía
  • Tomografía axial computarizada (procedimiento)
  • Tomografía computarizada (TC)
  • Escaneo de gato de diagnóstico
  • Tipo de servicio de escaneo de gato de diagnóstico

Undergo blood and urine sample collection

Otros nombres:
  • Recolección de muestras biológicas
  • Muestra biológica recolectada
  • Coleccion de especimenes
  • Recolección de muestras

Given IV

Otros nombres:
  • Tecentriq
  • MPDL3280A
  • RO5541267
  • RG7446
  • MPDL328OA
  • MPDL-3280A
  • RG-7446
  • RG 7446
  • RO 5541267
  • RO-5541267

Given IV

Otros nombres:
  • Imfinzi
  • Inmunoglobulina G1, anti-(proteína humana B7-H1) (cadena pesada monoclonal humana MEDI4736), disulfuro con cadena kappa monoclonal humana MEDI4736, dímero
  • MEDI-4736
  • MEDI4736
  • MEDIO 4736

Undergo optional tumor biopsy

Otros nombres:
  • Caja
  • BIOPSIA_TIPO
  • Biopsia
Experimental: Phase II, Arm I (iadademstat, atezolizumab, durvalumab)

Patients in Phase II Arm I receive iadademstat PO on days 1, 8, 15, and 22 or days 1 and 15 of each cycle. Patients also continue receiving their initial ICI treatment, either atezolizumab IV over 30-60 minutes on day 1 of each cycle or durvalumab IV over 60 minutes on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MUGA or ECHO, brain MRI or brain CT during screening, and CT scans and blood and urine sample collection throughout the trial. Patients may also undergo an optional tumor biopsy on study.

Undergo MRI

Otros nombres:
  • Resonancia magnética
  • Resonancia magnetica
  • Exploración de imágenes por resonancia magnética
  • Imágenes Médicas, Resonancia Magnética / Resonancia Magnética Nuclear
  • SRES
  • Imágenes de RM
  • Imágenes de RMN
  • RMN
  • Imágenes de resonancia magnética nuclear
  • Imágenes por resonancia magnética (IRM)
  • resonancia magnética nuclear
  • Imágenes por resonancia magnética (procedimiento)
  • Resonancias magnéticas
  • Resonancia magnética estructural

Undergo ECHO

Otros nombres:
  • Ecocardiografía
  • CE

Undergo MUGA

Otros nombres:
  • Exploración de la piscina de sangre
  • Angiografía con radionúclidos de equilibrio
  • Imagen de piscina de sangre cerrada
  • MUGA
  • Ventriculografía con radionúclidos
  • RNVG
  • Escaneo SIMA
  • Escaneo de adquisición sincronizado de múltiples puertas
  • Escaneo MUGA
  • Escaneo de adquisición de puertas múltiples
  • Exploración de ventriculograma con radionúclidos
  • Escaneo de grupo de corazón cerrado
  • Escaneo RNV

Undergo CT scan

Otros nombres:
  • Connecticut
  • GATO
  • Análisis de gato
  • Tomografía Axial Computarizada
  • Tomografía axial computarizada
  • Tomografía computarizada
  • tomografía
  • Tomografía axial computarizada (procedimiento)
  • Tomografía computarizada (TC)
  • Escaneo de gato de diagnóstico
  • Tipo de servicio de escaneo de gato de diagnóstico

Undergo blood and urine sample collection

Otros nombres:
  • Recolección de muestras biológicas
  • Muestra biológica recolectada
  • Coleccion de especimenes
  • Recolección de muestras

Given IV

Otros nombres:
  • Tecentriq
  • MPDL3280A
  • RO5541267
  • RG7446
  • MPDL328OA
  • MPDL-3280A
  • RG-7446
  • RG 7446
  • RO 5541267
  • RO-5541267

Given IV

Otros nombres:
  • Imfinzi
  • Inmunoglobulina G1, anti-(proteína humana B7-H1) (cadena pesada monoclonal humana MEDI4736), disulfuro con cadena kappa monoclonal humana MEDI4736, dímero
  • MEDI-4736
  • MEDI4736
  • MEDIO 4736

Undergo optional tumor biopsy

Otros nombres:
  • Caja
  • BIOPSIA_TIPO
  • Biopsia

Given PO

Otros nombres:
  • ORIA 1001
  • ORY-1001
  • RG 6016
  • RG6016
  • RO 7051790
  • RO7051790
  • trans-N1-((1R,2S)-2-fenilciclopropil)-1,4-ciclohexanodiamina

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Progression free survival
Periodo de tiempo: From start of treatment to time of progression or death, whichever occurs first, up to 2 years

Will be estimated using the method of Kaplan and Meier and will be presented with 95% confidence intervals as measure of effect size.

From start of treatment to time of progression or death, whichever occurs first, up to 2 years

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Incidencia de eventos adversos
Periodo de tiempo: Hasta 30 días después de la última dosis del tratamiento del estudio
Hasta 30 días después de la última dosis del tratamiento del estudio
Tasa de respuesta objetiva
Periodo de tiempo: Hasta 2 años
Hasta 2 años
Overall survival
Periodo de tiempo: Up to 2 years

Will be estimated using the method of Kaplan and Meier and will be presented with 95% confidence intervals as measure of effect size.

Up to 2 years

Otras medidas de resultado

Medida de resultado
Periodo de tiempo
Impacto de iadademstat en la correlación de los inhibidores de puntos de control inmunológico (ICI) y la presencia de caquexia
Periodo de tiempo: Hasta 2 años
Hasta 2 años
Relaciones exposición-respuesta de iadademstat en combinación con ICI
Periodo de tiempo: Hasta 2 años
Hasta 2 años
Cambios en el subtipo de cáncer de pulmón de células pequeñas
Periodo de tiempo: Hasta 2 años
Hasta 2 años
Detección de enfermedad residual mínima del ácido desoxirribonucleico tumoral circulante.
Periodo de tiempo: Hasta 2 años
Hasta 2 años

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Charles M Rudin, JHU Sidney Kimmel Comprehensive Cancer Center LAO

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

8 de abril de 2025

Finalización primaria (Estimado)

25 de julio de 2029

Finalización del estudio (Estimado)

25 de julio de 2029

Fechas de registro del estudio

Enviado por primera vez

29 de febrero de 2024

Primero enviado que cumplió con los criterios de control de calidad

29 de febrero de 2024

Publicado por primera vez (Actual)

1 de marzo de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

13 de noviembre de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • NCI-2024-01398
  • UM1CA186691 (Subvención/contrato del NIH de EE. UU.)
  • NCI-2024-01398 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
  • 10629 (Otro identificador: CTEP)
  • 10629 (Otro identificador: JHU Sidney Kimmel Comprehensive Cancer Center LAO)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .